Table: Towa Pharmaceutical -9-MTH group results
Feb 8 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2015 Dec 31, 2014 Mar 31, 2016
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 61.23 53.06 82.00
(+15.4 pct) (+17.3 pct) (+14.7 pct)
Operating 8.92 8.61 11.50
(+3.6 pct) (+34.8 pct) (+3.6 pct)
Recurring 8.93 12.51 11.50
(-28.6 pct) (+64.6 pct) (-25.5 pct)
Net 6.31 8.91 8.20
(-29.2 pct) (+73.3 pct) (-26.2 pct)
EPS 378.34 yen 524.01 yen 493.60 yen
EPS Diluted 359.20 yen
Ann Div 95.00 yen 95.00 yen
-Q2 div 47.50 yen 37.50 yen
-Q4 div 57.50 yen 47.50 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results